TR200102012T2 - Yumurtalık kanserinin tedavi yöntemleri, poli (fosfoester) bileşimler ile bunlara ait biyolojik olarak parçalanabilir maddeler. - Google Patents

Yumurtalık kanserinin tedavi yöntemleri, poli (fosfoester) bileşimler ile bunlara ait biyolojik olarak parçalanabilir maddeler.

Info

Publication number
TR200102012T2
TR200102012T2 TR2001/02012T TR200102012T TR200102012T2 TR 200102012 T2 TR200102012 T2 TR 200102012T2 TR 2001/02012 T TR2001/02012 T TR 2001/02012T TR 200102012 T TR200102012 T TR 200102012T TR 200102012 T2 TR200102012 T2 TR 200102012T2
Authority
TR
Turkey
Prior art keywords
experiment
phosphoester
ovarian cancer
antineoplastic agent
poly
Prior art date
Application number
TR2001/02012T
Other languages
English (en)
Inventor
Dang Wenbin
Original Assignee
Guilford Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guilford Pharmaceuticals Inc. filed Critical Guilford Pharmaceuticals Inc.
Publication of TR200102012T2 publication Critical patent/TR200102012T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/908—Mechanical repair performed/surgical
    • Y10S977/911—Cancer cell destruction
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/908—Mechanical repair performed/surgical
    • Y10S977/912—Cancer cell repair

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biological Depolymerization Polymers (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Yumurtalik kanseri memeli deneyin tedavisinde pertion içine verilmeye elverisli biyolojik olarak parçalanabilir polimer bilesimleri açiklanmaktadir. Bilesim (a) en azindan bir antineoplastik ajan ile (b) biyolojik olarak parçalanabilir bir fosfoester polimeri ihtiva eder. Burada polimer bilesimi antineoplastik ajanin deneyin peritonu içine uzatilmis süre ile verilebilmesini saglar. Deneye antineoplastik ajanla birlikte verilen polimer bilesimi, ayni dozaja sahip ancak bulusa konu biyolojik olarak parçalanabilir polimer olmaksizin deneye verilen antineoplastik ajanin sagladigi hayatta kalma oranini en azindan %10 arttirmaktadir. Yumurtalik kanserinin tedavisiyle ilgili kati madde ve yöntemler de tariflenmektedir.
TR2001/02012T 1999-01-11 1999-12-23 Yumurtalık kanserinin tedavi yöntemleri, poli (fosfoester) bileşimler ile bunlara ait biyolojik olarak parçalanabilir maddeler. TR200102012T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/227,852 US6350464B1 (en) 1999-01-11 1999-01-11 Methods for treating ovarian cancer, poly (phosphoester) compositions, and biodegradable articles for same

Publications (1)

Publication Number Publication Date
TR200102012T2 true TR200102012T2 (tr) 2002-01-21

Family

ID=22854735

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/02012T TR200102012T2 (tr) 1999-01-11 1999-12-23 Yumurtalık kanserinin tedavi yöntemleri, poli (fosfoester) bileşimler ile bunlara ait biyolojik olarak parçalanabilir maddeler.

Country Status (20)

Country Link
US (4) US6350464B1 (tr)
EP (1) EP1140028B1 (tr)
JP (1) JP2002534456A (tr)
KR (1) KR20010101472A (tr)
CN (1) CN1337878A (tr)
AT (1) ATE310506T1 (tr)
AU (1) AU779182B2 (tr)
BR (1) BR9916881A (tr)
CA (1) CA2359109C (tr)
CZ (1) CZ20012416A3 (tr)
DE (1) DE69928567T2 (tr)
HU (1) HUP0202670A3 (tr)
IL (2) IL145087A0 (tr)
IN (1) IN2001CH01053A (tr)
MX (1) MX236541B (tr)
NO (1) NO20013402L (tr)
RU (1) RU2001122708A (tr)
TR (1) TR200102012T2 (tr)
WO (1) WO2000041678A1 (tr)
ZA (1) ZA200106499B (tr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1096957A1 (en) 1998-06-18 2001-05-09 Johns Hopkins University School of Medicine Methods and reagents for intramuscular delivery of nucleic acids
US6537585B1 (en) * 1999-03-26 2003-03-25 Guilford Pharmaceuticals, Inc. Methods and compositions for treating solid tumors
AU6536400A (en) * 1999-08-11 2001-03-05 Alkermes Controlled Therapeutics, Inc. Method of delivering a chemotherapeutic agent to a solid tumor
WO2002003957A2 (en) * 2000-07-07 2002-01-17 Guilford Pharmaceuticals, Inc. Compositions for sustained release of antineoplastic taxanes, and methods of making and using the same
WO2002005800A2 (en) * 2000-07-17 2002-01-24 Guilford Pharmaceuticals, Inc. Compositions for sustained release of analgesic agents, and methods of making and using the same
WO2002028372A2 (en) * 2000-10-06 2002-04-11 Johns Hopkins University Systemic delivery of compounds through non-invasive bladder administration
US20020198135A1 (en) * 2000-10-12 2002-12-26 Wenbin Dang Compositions for release of radiosensitizers, and methods of making and using the same
US20020141966A1 (en) * 2000-11-16 2002-10-03 Wenbin Dang Compositions for treatment of malignant effusions, and methods of making and using the same
WO2003007914A2 (en) * 2001-07-19 2003-01-30 Guilford Pharmaceuticals, Inc. Biocompatible polymer containing composition for treatment of prostate cancers
WO2003007915A2 (en) * 2001-07-19 2003-01-30 Guilford Pharmaceuticals, Inc. Compositions for treatment of head and neck cancers, and methods of making and using the same
US20050238616A1 (en) * 2002-01-09 2005-10-27 Guilford Pharmaceuticals, Inc. Compositions for treatment of central nervous system neoplasms, and methods of making and using the same
ITMI20020680A1 (it) * 2002-03-29 2003-09-29 Acs Dobfar Spa Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento
US20050244402A1 (en) * 2004-04-30 2005-11-03 Villanueva Julie M Absorption of pain-causing agents
WO2006002365A2 (en) * 2004-06-24 2006-01-05 Angiotech International Ag Microparticles with high loadings of a bioactive agent
US8563328B2 (en) * 2004-07-26 2013-10-22 University Of Louisville Research Foundation, Inc. Fiber-optic biosensor and biosensing methods
US7871573B2 (en) * 2004-07-26 2011-01-18 University Of Louisville Research Foundation, Inc. Enhancement of sensitivity of fluorophore mediated biosensing and bioimaging
US7517914B2 (en) * 2005-04-04 2009-04-14 Boston Scientificscimed, Inc. Controlled degradation materials for therapeutic agent delivery
US8580814B2 (en) * 2006-04-03 2013-11-12 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
GB0525864D0 (en) * 2005-12-20 2006-02-01 Novartis Ag Organic compounds
EP3061791B1 (en) 2006-07-20 2019-01-16 OrbusNeich Medical, Inc. Bioabsorbable polymeric composition for a medical device
US20090169628A1 (en) 2006-10-17 2009-07-02 Armark Authentication Technologies, Llc Article and method for focused delivery of therapeutic and/or diagnostic materials
US7959942B2 (en) 2006-10-20 2011-06-14 Orbusneich Medical, Inc. Bioabsorbable medical device with coating
EP2073754A4 (en) 2006-10-20 2012-09-26 Orbusneich Medical Inc BIOABSORBABLE POLYMER COMPOSITION AND MEDICAL DEVICE BACKGROUND
CA2709712C (en) 2007-12-20 2016-05-10 Surmodics Pharmaceuticals, Inc. Process for preparing microparticles having a low residual solvent volume
EP2242481A1 (en) * 2007-12-31 2010-10-27 Armark Authentication Technologies, LLC Article and method for focused delivery of therapeutic and/or diagnostic materials
US20100078848A1 (en) * 2008-09-29 2010-04-01 Armark Authentication Technologies, Llc Spinneret and method of spinning fiber
US20100291214A1 (en) * 2008-12-23 2010-11-18 Armark Authentication Technologies, Llc Three-dimensional microfiber extrudate structure and process for forming three-dimensional microfiber extrudate structure
WO2010132763A1 (en) * 2009-05-15 2010-11-18 Armark Authentication Technologies, Llc Fiber having non-uniform composition and method for making same
JP2014523444A (ja) * 2011-07-19 2014-09-11 エスティーシー． ユーエヌエム 癌の炎症性環境に基づいて治療用積載物を放出する、腹腔内投与されるナノ担体
US10058688B2 (en) * 2012-05-09 2018-08-28 Massachusetts Institute Of Technology Medicament, method, and drug delivery device for treatment of ovarian cancer

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA597473A (en) 1960-05-03 Starck Werner Process for the manufacture of phosphorus-containing polyesters and copolymers thereof
US2891915A (en) 1954-07-02 1959-06-23 Du Pont Organophosphorus polymers
US3271329A (en) 1958-09-19 1966-09-06 Eastman Kodak Co Method for producing polymers derived from phosphites and glycols
US3442982A (en) 1965-10-15 1969-05-06 Weston Chemical Corp Polyphosphites of 2,2-dimethyl-3-hydroxypropyl - 2 - dimethyl - 3-hydroxypropionate
FR2219193B1 (tr) 1973-02-28 1976-05-21 Rhone Poulenc Sa
US3932566A (en) 1974-09-16 1976-01-13 Celanese Corporation Phosphonate polymers
US4100354A (en) 1976-08-05 1978-07-11 Owens-Corning Fiberglass Corporation Terephthalate ester polyols
US4259222A (en) 1978-08-16 1981-03-31 Basf Wyandotte Corporation Linear saturated polyesters of phosphoric acid and halogenated diols as flame-retardant additives and coatings
DE2925206A1 (de) 1979-06-22 1981-01-29 Bayer Ag Aromatische polyesterphosphonate, verfahren zu ihrer herstellung und ihre verwendung zur herstellung thermoplastischer formkoerper
FR2498612A1 (fr) 1981-01-26 1982-07-30 Peters Ligatures Nouveaux polymeres insolubles a biodegradabilite reglable a volonte, leurs procedes de preparation et leur application en tant que biomateriaux
US4757128A (en) 1986-08-01 1988-07-12 Massachusetts Institute Of Technology High molecular weight polyanhydride and preparation thereof
US4474937A (en) 1983-10-03 1984-10-02 The Dow Chemical Company Phosphorus-modified polyestercarbonate resins
US4481353A (en) 1983-10-07 1984-11-06 The Children's Medical Center Corporation Bioresorbable polyesters and polyester composites
US4746462A (en) 1985-02-21 1988-05-24 Dainichiseika Color & Chemicals Mfg. Co., Ltd. Phosphoric ester compound
US4789724A (en) 1986-10-17 1988-12-06 Massachusetts Institute Of Technology Preparation of anhydride copolymers
US4978332A (en) 1987-09-28 1990-12-18 Matrix Pharmaceutical, Inc. Treatments employing vasoconstrictive substances in combination with cytotoxic agents for introduction into cellular lesion areas
US5256765A (en) 1989-03-09 1993-10-26 The Johns Hopkins University School Of Medicine Biodegradable poly(phosphate esters)
US5194581A (en) 1989-03-09 1993-03-16 Leong Kam W Biodegradable poly(phosphoesters)
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
ZA918168B (en) 1990-10-16 1993-04-14 Takeda Chemical Industries Ltd Prolonged release preparation and polymers thereof.
US5429634A (en) 1993-09-09 1995-07-04 Pdt Systems Biogenic implant for drug delivery and method
US5716981A (en) 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
ATE220894T1 (de) 1993-12-29 2002-08-15 Matrix Pharma Zusammensetzung für lokale freigabe von zytostatika
DE4404365A1 (de) 1994-02-11 1995-08-17 Cassella Ag Phosphin- und phosphonsäuregruppenhaltige Polykondensate
US5626862A (en) 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
WO1996022786A1 (en) 1995-01-23 1996-08-01 Takeda Chemical Industries, Ltd. Sustained-release preparation and use
US5637085A (en) 1995-11-20 1997-06-10 Cardinale; Robert M. Method of cancer tumor treatment by slow release delivery of 1,2,4-benzotriazine oxides to tumor site
JP3155013B2 (ja) 1996-04-23 2001-04-09 キナートン・リミテッド 酸性ポリ乳酸ポリマー
US5993856A (en) 1997-01-24 1999-11-30 Femmepharma Pharmaceutical preparations and methods for their administration
EP1007029A4 (en) 1997-03-27 2003-03-26 Baker Norton Pharma METHODS AND COMPOSITIONS FOR THE TREATMENT OF OVARY CANCER
UA54505C2 (uk) 1997-04-03 2003-03-17 Гілфорд Фармасьютікалз Інк. Полімери, що біологічно розкладаються, зшиті фосфатами, композиції, вироби і способи для їх виготовлення і використання
KR20010006026A (ko) 1997-04-03 2001-01-15 존스 홉킨스 유니버시티 스쿨 오브 메디슨 생물분해성 테레프탈레이트 폴리에스테르-폴리(포스페이트) 중합체, 조성물, 약품 및 그의 제조방법과 이용방법
US5912225A (en) 1997-04-14 1999-06-15 Johns Hopkins Univ. School Of Medicine Biodegradable poly (phosphoester-co-desaminotyrosyl L-tyrosine ester) compounds, compositions, articles and methods for making and using the same
NZ501184A (en) 1997-04-30 2002-08-28 Guilford Pharm Inc Biodegradable poly (phosphodiester) compositions that degrade in vivo into non-toxic residues
WO1998058012A1 (en) 1997-06-18 1998-12-23 Guilford Pharmaceuticals Inc. Two-stage solution polymerization of high molecular weight poly(phosphoesters)
US6028163A (en) 1997-06-27 2000-02-22 Guilford Pharmaceuticals Inc. Solution polymerization of high molecular weight poly(phosphoesters) in toluene
US6419709B1 (en) 1998-10-02 2002-07-16 Guilford Pharmaceuticals, Inc. Biodegradable terephthalate polyester-poly(Phosphite) compositions, articles, and methods of using the same
US6153212A (en) * 1998-10-02 2000-11-28 Guilford Pharmaceuticals Inc. Biodegradable terephthalate polyester-poly (phosphonate) compositions, articles, and methods of using the same
EP1117441A2 (en) 1998-10-02 2001-07-25 Guilford Pharmaceuticals Inc. Biodegradable terephthalate polyester-poly(phosphonate) and polyester-poly(phosphite) compositions, articles, and methods of using them
US6537585B1 (en) * 1999-03-26 2003-03-25 Guilford Pharmaceuticals, Inc. Methods and compositions for treating solid tumors
CA2369740A1 (en) 1999-04-22 2000-11-02 American Biosciences, Inc. Long term administration of pharmacologically active agents

Also Published As

Publication number Publication date
HUP0202670A3 (en) 2003-02-28
IL145087A0 (en) 2002-06-30
EP1140028A1 (en) 2001-10-10
HUP0202670A2 (hu) 2002-11-28
US20030138493A1 (en) 2003-07-24
CA2359109C (en) 2011-02-22
EP1140028B1 (en) 2005-11-23
JP2002534456A (ja) 2002-10-15
KR20010101472A (ko) 2001-11-14
US20010038849A1 (en) 2001-11-08
MX236541B (es) 2006-05-04
ATE310506T1 (de) 2005-12-15
DE69928567T2 (de) 2006-08-17
IL144087A0 (en) 2002-05-23
CN1337878A (zh) 2002-02-27
ZA200106499B (en) 2002-11-07
CA2359109A1 (en) 2000-07-20
AU2059100A (en) 2000-08-01
US6479067B2 (en) 2002-11-12
US6641833B2 (en) 2003-11-04
AU779182B2 (en) 2005-01-13
WO2000041678A1 (en) 2000-07-20
RU2001122708A (ru) 2004-02-20
BR9916881A (pt) 2002-05-07
NO20013402D0 (no) 2001-07-09
US20040071774A1 (en) 2004-04-15
DE69928567D1 (de) 2005-12-29
IN2001CH01053A (en) 2005-03-04
MXPA01007018A (es) 2005-07-01
US6350464B1 (en) 2002-02-26
NO20013402L (no) 2001-09-11
CZ20012416A3 (cs) 2001-11-14

Similar Documents

Publication Publication Date Title
TR200102801T2 (tr) Solid tümörlerin tedavisine yönelik yöntem ve bileşimler
BR9916881A (pt) Métodos para tratamento do câncer ovariano, composições de poli(fosfoéster) e artigos biodegradáveis das mesmas
BRPI0612845A8 (pt) composto, formulação farmacêutica, métodos para tratar câncer e para sintetizar um composto de fórmula alq-dispasador
PT1061900E (pt) Composicoes e metodos para libertacao de uma droga
EP1015008A4 (en) COMPOUNDS AND COMPOSITIONS FOR DELIVERY OF ACTIVE AGENTS
TR200002299T2 (tr) Epotilon kompozisyonları.
DE69925276D1 (de) Stoffe und zusammensetzungen für die verabreichung aktiver substanzen
GEP20043375B (en) APRIL-Receptor (BCMA) and Use Thereof
TR200707263T2 (tr) Uzun sürede dışarıya yayılan eritromisin türevi formülleri.
CA2247848A1 (en) Nitric oxide donors capable of reducing toxicity from drugs
MY162319A (en) Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
AR023616A1 (es) Preparaciones combinadas que comprenden derivados de antraciclina
BR9908391A (pt) Composição antitumural contendo uma combinação sinergìstica de um derivado de antraciclina com um derivado de camptotecina
BR0015256A (pt) Composições farmacêuticas contendo uma droga de antibiótico de fluoroquinolona e uma goma de xantano
BR0113148A (pt) Composições de 2-piridinamina e métodos relacionados
ES2150404T3 (es) Composiciones farmaceuticas de tizoxanida y nitozoxanida.
TR200101766T2 (tr) Dehidroepiandrosteronun klatratları ve bunlara tekabül eden kompozisyonlar
CY1109541T1 (el) Φαρμακευτικη συνταγοποιηση για την θεραπεια οστεοαρθριτιδας η οποια περιεχει κλοδρονικο οξυ και υαλουρονικο οξυ
TR200001724T2 (tr) 5-HT1F Agonistleri
NZ523606A (en) Pharmaceutical compositions and methods for use
DK1135169T3 (da) Anvendelse af et farmaceutisk præparat indeholdende et anticancermiddel og mindst et peptid.
AU6749401A (en) Use of aloe-emodin in the treatment of neuroectodermal tumors
BRPI0416870A (pt) composições anticáncer sinergìticas
WO2004073648A3 (en) Composition and methods for inhibiting cell survival
AU7338500A (en) Methods and compositions for treating autoimmune disease